MHRA/CHM ADVICE (UPDATED DECEMBER 2019): DOMPERIDONE
FOR NAUSEA AND VOMITING: LACK OF EFFICACY IN CHILDREN;
REMINDER OF CONTRA-INDICATIONS IN ADULTS AND
ADOLESCENTS
Domperidone is no longer indicated for the relief of
nausea and vomiting in children aged under 12 years or
those weighing less than 35 kg. A European review
concluded that domperidone is not as effective in this
population as previously thought and alternative
treatments should be considered. Healthcare
professionals are advised to adhere to the licensed dose
and to use the lowest effective dose for the shortest
possible duration (max. treatment duration should not
usually exceed 1 week).
Healthcare professionals are also reminded of the
existing contra-indications for use of domperidone (see
Contra-indications, Hepatic impairment, and Interactions).
PDF page 473
→Appendix 1: domperidone
PDF page 473
▶Common or very common Dry mouth
▶Uncommon Anxiety. asthenia. breast abnormalities.
diarrhoea. drowsiness. headache. lactation disorders.
libido loss
▶Frequency not known Arrhythmias. depression.
gynaecomastia. menstrual cycle irregularities. movement
disorders. oculogyric crisis. QT interval prolongation.
seizure. sudden cardiac death. urinary retention
PDF page 473
Use only if potential benefit outweighs risk.
PDF page 473
Amount too small to be harmful.
PDF page 473
Manufacturer advises avoid in
moderate to severe impairment.
PDF page 473
Dose adjustments Reduce frequency.
PDF page 473